New perspectives in polycystic ovary syndrome

Trends in Endocrinology and Metabolism

Volumn 7, Issue 8, 1996, Pages 267-271

  Diamanti Kandarakis, Evanthia ^a   Dunaif, Andrea ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN; GONADOTROPIN; INSULIN;

ANOVULATION; CLINICAL FEATURE; FEMALE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW;

EID: 0030272074     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(96)00125-7     Document Type: Short Survey

References (42)

1. Achard C, Thiers J: 1921. Le virilisme pilaire et son association à l'insuffisance glycolytique (diabète des femmes a barb). Bull Acad Natl Med 86:51-64.
2. Burghen GA, Givens RJ, Kitabchi AE: 1980. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50:113-116.
3. Carey AH, Chan KL, Short F, et al.: 1993. Evidence for a single gene effect in polycystic ovaries and male pattern baldness. Clin Endocrinol (Oxf) 38:653-658.
4. Carey AH, Waterworth D, Patel K, et al.: 1994. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 3:1873-1876.
5. Caro JF, Dohm LG, Pories WG, et al.: 1989. Cellular alterations in liver, skeletal muscle, and adipose tissue responsible for insulin resistance in obesity and type II diabetes. Diabetes Metab Rev 5:665-689.
6. Ciaraldi TP, El-Roeiy A, Madar Z, et al.: 1992. Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab 75:577-583.
7. Crowley WF: 1996. New tools for pituitary-gonadal assessment. In Filicori M, ed. The Ovary: Regulation, Dysfunction and Treatment. Amsterdam, Elsevier (in press).
8. Dahlgren E, Johansson S, Lindstedt G, et al.: 1992a. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57:505-513.
9. Dahlgren E, Janson PO, Johansson S, et al.: 1992b. Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 71:599-603.
10. Dunaif A: 1992. Insulin resistance and ovarian hyperandrogenism. Endocrinologist 2:248-260.
11. Dunaif A, Finegood DT: 1996. β-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942-947.
12. Dunaif A, Anderson R, Chapin D, et al.: 1984. The effects of continuous androgen secretion upon the hypothalamic-pituitary-axis in women: evidence from a luteinized thecoma of the ovary. J Clin Endocrinol Metab 59:389-393.
13. Dunaif A, Hoffman AR, Scully RE, et al.: 1985. The clinical, biochemical, and ovarian morphologic features in women with acanthosis nigricans and masculinization. Obstet Gynecol 66:545-552.
14. Dunaif A, Graf M, Mandeli J, et al.: 1987. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 65:499-507.
15. Dunaif A, Futterweit W, Segal KR, et al.: 1989. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 38:1165-1174.
16. Dunaif A, Givens JR, Haseltine F, Merriam GR, eds.: 1992a. The Polycystic Ovary Syndrome. Cambridge, MA, Blackwell Scientific.
17. Dunaif A, Segal KR, Shelley DR, et al.: 1992b. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 41:1257-1266.
18. Dunaif A, Xia J, Book C, et al.: 1995. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96:801-810.
19. Dunaif A, Scott D, Finegood D, et al.: 1996. The insulin sensitizing agent troglitazone: a novel therapy for the polycystic ovary syndrome. J Clin Endocrinol Metab (in press).
20. Ehrmann DA, Barnes RB, Rosenfield RL: 1995. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr Rev 16:322-353.
21. Erickson GF: 1995. The Ovarian Connection. In Adashi EY, Rock JA, Rosenwaks Z, eds. Reproductive Endocrinology, Surgery, and Technology. New York, Raven Press, pp 1141-1160.
22. Franks S: 1995. Polycystic ovary syndrome. N Engl J Med 333:853-861.
23. Franks S, Mason H, White D, et al.: 1996. Mechanisms of Anovulation in Polycystic Ovary Syndrome. In Filicori M, ed. The Ovary: Regulation, Dysfunction and Treatment. Amsterdam, Elsevier (in press).
24. Futterweit W, Deligdisch L: 1985. Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 62:16-21.
25. Harris MI, Hadden WC, Knowler WC, et al.: 1987. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 36:523-534.
26. Lanzone A, Caruso A, DiSimone N, et al.: 1995. Polycystic ovary disease: a risk factor for gestational diabetes? J Reprod Med 40:312-316.
27. Legro RS, Fox J, Dunaif A: 1994. Insulin resistance is a potential phenotypic marker for familial polycystic ovary syndrome (PCOS) [abst]. Proceedings of the 50th Annual Meeting of the American Fertility Society, San Antonio, TX.
28. Legro RS, Coleman KH, Irwin L, et al.: 1995. Polycystic ovary syndrome over age 40: age related differences in phenotype [abst]. Proceedings of the 42nd Annual Meeting of the Society for Gynecologic Investigation, Chicago, IL.
29. Maddux BA, Sbraccia P, Kumakura S, et al.: 1995. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 373:448-451.
30. Mechanick J, Dunaif A: 1990. Masculinization: a clinical approach to the diagnosis and treatment of hyperandrogenic women. In Mazzaferri E, ed. Advances in Endocrinology and Metabolism. Chicago, IL, Mosley Year Book, pp 129-173.
31. Moghetti P, Tosi F, Castello R, et al.: 1996. Antiandrogens and insulin action. J Clin Endocrinol Metab 81:952-960.
32. Nagamani M, Dinh TV, Kelver ME: 1986. Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol 154:384-389.
33. Polderman KH, Gooren JG, Asscherman H, et al.: 1994. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79:265-271.
34. Poison DW, Wadsworth J, Adams J, et al.: 1988. Polycystic ovaries: a common finding in normal women. Lancet 1:870-872.
35. Robinson S, Kiddy D, Gelding SV, et al.: 1993. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries. Clin Endocrinol (Oxf) 39:351-355.
36. Rosenbaum D, Haber RS, Dunaif A: 1993. Insulin resistance in polycystic ovary syndrome: decreased expression of GLUT-4 glucose transporters in adipocytes. Am J Physiol 264:E197-E202.
37. Sorbara LR, Tang Z, Cama A, et al.: 1994. Absence of insulin receptor gene mutations in three women with the polycystic ovary syndrome. Metabolism 43:1568-1574.
38. Taylor SI, Cama A, Accili D, et al.: 1992. Mutations in the insulin receptor gene. Endocr Rev 13:566-595.
39. Weiss DJ, Charles MA, Dunaif A, et al.: 1994. Hyperinsulinemia is associated with menstrual irregularity and altered serum androgens in Pima Indian women. Metabolism 43: 803-807.
40. Wild RA, Grubb BG, Hartz A, et al.: 1990. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 54: 255-259.
41. Zerah M, Rheaume E, Mani P, et al.: 1994. No evidence of mutations in the genes for type I and II 3β-hydroxysteroid dehydrogenase (3BHSD) in nonclassical 3BHSD deficiency. J Clin Endocrinol Metab 79:1811-1817.
42. Zhang L, Rodriquez H, Ohno S, et al.: 1995. Serine phosphorylation of human P450c17 increases 17,20 lyase activity: implications for adrenarche and the polycystic ovary syndrome. Proc Natl Acad Sci USA 92:10,619-10,623.